viewCardieX Ltd

Atcor Medical to trial its technology with wearable cardio monitors

Home monitoring using modern wearables and mobile products is a growth industry.

a heart and a stethoscope
The first phase is expected to take about eight weeks to complete

Atcor Medical Holdings Limited (ASX:ACG) is commencing a preliminary trial of its Pulse Wave Analysis (PWA) technology in a strategic collaboration with Silicon Valley-based Blumio Inc.

As part of the eight-week trial, AtCor will assess the feasibility of obtaining cardiovascular blood pressure (BP) related data utilising the Blumio wearable sensor and analysing it via AtCor's PWA technology.

As part of a multi-phase program, the first phase of the assessment is to collect sensor data from at least 15 human subjects covering different age groups, different genders and a range of BP characteristics.

Collaborating with Macquarie University

The trial will be conducted in collaboration with a team headed by Professor Alberto Avolio in the Faculty of Medicine and Health Sciences at Macquarie University, Sydney.

Pending success of the first phase trial results, subsequent trials will progress to integrate AtCor's PWA technologies into an existing Blumio wearable sensor product.

The first phase is expected to take about eight weeks to complete, including the trial, technical report and stakeholder analysis.

Fast growing home monitoring segment

Cardiovascular related mortality accounts for over 30% of global deaths annually and home monitoring using modern wearables and mobile products is a growth industry expected to exceed US$1.6 billion by 2023.

Blumio and AtCor are aiming to be at the forefront of this developing area of telehealth and can leverage off their strong established client base such as Novartis, GSK, Mayo Clinic and others.

AtCor chief executive officer Craig Cooper said: “Collaborating with our first-class partners in this trial, Macquarie University and Blumio, ensures that AtCor has every opportunity to succeed in progressing its leading cardiovascular monitoring technology and encompasses our strategy to become a world leader in hypertension and cardiovascular health.”

Quick facts: CardieX Ltd


Price: 0.061 AUD

Market Cap: $56.49 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


CardieX releases first-half results as company achieves 5-year record high...

CardieX Ltd (ASX:CDX) CEO Craig Cooper joined Steve Darling from Proactive to share details about their half-yearly report. That report showed strong growth numbers as 2021 is looking to be a transformational year for the company. Half-year sales were up 30% for the first six months of FY2021...

on 2/3/21

2 min read